Clinical trial

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

NCT04803539

Study summary

ClinicalTrials.gov

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record capecitabine Normalized identity: capecitabine View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention capecitabine + camrelizumab + apatinib Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-04-01

PhasePHASE2 / PHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

capecitabineDRUG · verified · RxNorm: capecitabine

capecitabine + camrelizumab + apatinibDRUG

Sponsors & collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universitylead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04803539 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.